Intermediate filaments enable pathogen docking to trigger type 3 effector translocation
Type 3 secretion systems (T3SSs) of bacterial pathogens translocate bacterial effector proteins that mediate disease into the eukaryotic cytosol. Effectors traverse the plasma membrane through a translocon pore formed by T3SS proteins. In a genome-wide selection, we identified the intermediate filam...
Saved in:
Published in: | Nature microbiology Vol. 1; no. 4; p. 16025 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
London
Nature Publishing Group UK
07-03-2016
Nature Publishing Group |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Type 3 secretion systems (T3SSs) of bacterial pathogens translocate bacterial effector proteins that mediate disease into the eukaryotic cytosol. Effectors traverse the plasma membrane through a translocon pore formed by T3SS proteins. In a genome-wide selection, we identified the intermediate filament vimentin as required for infection by the T3SS-dependent pathogen
S. flexneri
. We found that vimentin is required for efficient T3SS translocation of effectors by
S. flexneri
and other pathogens that use T3SS,
Salmonella enterica
serovar Typhimurium and
Yersinia pseudotuberculosis.
Vimentin and the intestinal epithelial intermediate filament keratin 18 interact with the C-terminus of the
Shigella
translocon pore protein IpaC. Vimentin and its interaction with IpaC are dispensable for pore formation, but are required for stable docking of
S. flexneri
to cells; moreover, stable docking triggers effector secretion. These findings establish that stable docking of the bacterium specifically requires intermediate filaments, is a process distinct from pore formation, and is a prerequisite for effector secretion.
Binding of type 3 secretion system translocons to host intermediate filaments mediate
Shigella
,
Salmonella
and
Yersinia
docking and facilitate effector translocation. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Current Affiliations: Liver Diseases Therapeutic Area, Gilead Sciences, Foster City, CA 94404, USA Current Affiliations: Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA Current Affiliations: Netherlands Cancer Institute, 1066 CX, Amsterdam, NL Current Affiliations: Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, MA 02114, USA |
ISSN: | 2058-5276 2058-5276 |
DOI: | 10.1038/nmicrobiol.2016.25 |